Test Story

By: NewsUSA

March 27, 2025 at 20:00 PM EDT

(NewsUSA) - For more details, including important safety information, on VenaSeal, visit: https://www.medtronic.com/breakfree.

Sources

Gloviczki P, Comerota AJ, Dalsing MC, et al. The care of patients with varicose veins and associated chronic venous diseases: Clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg. 2011;53(5 Suppl):2S–48S. doi: 10.1016/j.jvs.2011.01.079.

Mayo Clinic: Varicose Veinshttps://www.mayoclinic.org/diseases-conditions/varicose-veins/symptoms-causes/syc-20350643

National Heart Lung and Blood Institute: Varicose Veins https://www.nhlbi.nih.gov/health/varicose-veins

Morrison N, Gibson K, McEnroe S, et al. Randomized trial comparing cyanoacrylate embolization and radiofrequency ablation for incompetent great saphenous veins (VeClose). J Vasc Surg. 2015;61(4):985–994. doi: 10.1016/j.jvs.2014.11.071.

Proebstle T, Alm J, Dimitri S, et al. Three-year follow-up results of the prospective European multicenter cohort study on cyanoacrylate embolization for treatment of refluxing great saphenous veins. J Vasc Surg Venous Lymphat Disord. 2021;9(2):329–334. doi: 10.1016/j.jvsv.2020.05.019.

Almeida JI, Javier JJ, Mackay EG, Bautista C, Cher DJ, Proebstle TM. Thirty-sixth-month follow-up of first-in-human use of cyanoacrylate adhesive for treatment of saphenous vein incompetence. J Vasc Surg Venous Lymphat Disord. 2017;5(5):658–666. doi: 10.1016/j.jvsv.2017.03.016.

Symbol	Price	Change (%)
AMZN	225.09	+4.40 (1.99%)
AAPL	276.08	+4.59 (1.69%)
AMD	215.10	+11.32 (5.56%)
BAC	52.05	+0.49 (0.95%)
GOOG	317.68	+18.03 (6.02%)
META	614.23	+19.98 (3.36%)
MSFT	475.37	+3.25 (0.69%)
NVDA	182.22	+3.34 (1.87%)
ORCL	200.02	+1.26 (0.63%)
TSLA	418.49	+27.40 (7.00%)

Symbol

Price

Change (%)

AMZN

225.09

+4.40 (1.99%)

AAPL

276.08

+4.59 (1.69%)

AMD

215.10

+11.32 (5.56%)

BAC

52.05

+0.49 (0.95%)

GOOG

317.68

+18.03 (6.02%)

Test Story

More News

Recent Quotes